Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Pierre Sabouret: Despite the NEJM Publication, I Still Prefer DOACs
Nov 14, 2026, 23:15

Pierre Sabouret: Despite the NEJM Publication, I Still Prefer DOACs

Pierre Sabouret, Cardiologist, Member of the Executive Committee for Education at European Atherosclerosis Society, shared NEJM‘s post on X:

“Despite it’s published in NEJM, I’m still not convinced by aspirin in the prevention of venous thrombosis and will still prescribe DOAC in this setting.”

NEJM (The New England Journal of Medicine) shared a post on X:

“A trial of venous thromboembolism (VTE) prophylaxis after hip or knee arthroplasty did not show that aspirin was noninferior to rivaroxaban or warfarin for symptomatic VTE or death.

Warfarin and rivaroxaban were not noninferior to aspirin for safety.”

Title 1: Prevention of Venous Thromboembolism after Total Hip or Knee Replacement

Authors: Vincent D. Pellegrini Jr., Carol A. Lambourne, Laurence S. Magder, Patricia D. Franklin, Jay S. Magaziner, Brook I. Martin, Richard Iorio, Kevin L. Garvin, Michael A. Mont, Wayne E. Moschetti, Antonia F. Chen, David Warwick, C. McCollister Evarts, Adina Harri, Laura M. Kernan, Samuel Z. Goldhaber, William J. Maloney, Zeke J. Walton, James A. Browne, Harry A. Demos, James I. Huddleston III, Stephen L. Kates, Peter J. Brooks, Navin D. Fernando, Brock A. Lindsey, Matthew J. Dietz, James Nace, Ronald E. Delanois, Michael S. Kain, Mark J. Spangehl, Brent A. Lanting, Eric M. Cohen, Lisa K. Moores, William L. Healy, Charles W. Francis

Pierre Sabouret

Title 2: Aspirin Therapy — Enough after Arthroplasty?

Authors: John W. Eikelboom

Pierre Sabouret: Despite the NEJM Publication, I Still Prefer DOACs

Other posts featuring Pierre Sabouret on Hemostasis Today.